Abbott Labs (ABT +0.5%) ticks up after reporting positive trial results for the it's Absorb...
Monday, March 11, 3:57 PM ETAbbott Labs (ABT +0.5%) ticks up after reporting positive trial results for the it's Absorb Bioresorbable Vascular Scaffold. Results showed the rate of major adverse cardiovascular events in 101 patients was 10 percent at three years, similar to comparative data with a best-in-class drug eluting stent at the same follow-up period. Absorb is commercially available in Europe as well as other international markets and is an investigational device in the U.S.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles